About this trial
This study looks at how safe and effective acalabrutinib is compared to other treatment options for adults with Chronic Lymphocytic Leukemia (CLL) and heart issues. Participants will receive either acalabrutinib or a treatment chosen by their doctor. All participants have to have moderate to severe heart impairment as defined by specific heart function tests.
The trial's ID number is NCT06651970. It is a Phase 4 trial, which means it is looking at the safety and effectiveness of the treatment after it has been approved. The study plans to include about 60 participants and is regulated by the FDA.
Who can join
This trial is for adults 18 years and older, including both men and women. To join, participants must have CLL and moderate to severe heart issues. They should be able to follow the study schedule and provide consent. Some patients like those with certain infections or recent surgeries cannot participate. The study team will check eligibility before enrollment.
Conditions
Chronic Lymphocytic Leukaemia, Heart Failure
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly assigned to one of two groups. One group will take acalabrutinib, a medication taken by mouth twice a day. The other group will receive a treatment chosen by their doctor. Everyone will have regular check-ups to assess their health and treatment response throughout the study.
Where
This trial is running at 3 locations in the United States. 2 of them are currently recruiting.
Philadelphia, Pennsylvania
Charlotte, North Carolina